High-Dose Flu Vaccine: What It Is, Who Should Get It, and What the Safety Data Show

Each year, influenza-related complications lead to between 140,000 and 710,000 hospitalizations and between 12,000 and 52,000 deaths in the United States, according to CDC estimates. Adults aged 65 and older account for a disproportionate share of these outcomes — roughly 70–85% of flu-related deaths occur in this age group. The high-dose influenza vaccine was developed specifically to address a well-documented problem: the aging immune system produces a weaker antibody response to standard flu vaccines.

This article walks through the science behind the high-dose flu shot, what clinical trials have found, how side effects compare with standard-dose vaccines, and what the latest CDC guidance says for the 2026–2027 flu season.

What Is a High-Dose Flu Vaccine?

The high-dose influenza vaccine (marketed as Fluzone High-Dose Quadrivalent by Sanofi Pasteur) contains four times the amount of hemagglutinin antigen found in a standard flu shot — 60 micrograms per strain versus 15 micrograms. The higher antigen load is designed to provoke a stronger immune response in older adults whose immune systems have declined with age, a phenomenon known as immunosenescence.

The vaccine is approved by the FDA for adults aged 65 and older. It covers four influenza strains (two A and two B subtypes), matching the standard quadrivalent vaccine.

Hemagglutinin is the protein on the surface of the influenza virus that allows it to bind to host cells. Standard flu vaccines contain 15 µg of this protein per strain — a dose that reliably triggers antibody production in younger adults. But for adults in their 70s and 80s, this amount often fails to produce antibody levels high enough to protect against infection. By quadrupling the antigen dose, the high-dose formulation essentially compensates for the diminished capacity of an aging immune system to mount a response.

Why Older Adults Need a Stronger Flu Vaccine

The immune system does not decline all at once. It undergoes a gradual remodeling process that researchers have studied under the umbrella term “immunosenescence.” Understanding this process explains why a standard flu shot that works well in a 30-year-old may fall short in a 75-year-old.

What Happens to the Immune System After 65

Several changes take place in the aging immune system that directly affect vaccine response:

Thymic involution. The thymus — a small organ behind the breastbone where T cells mature — begins shrinking after puberty and continues to atrophy throughout life. By age 65, thymic tissue is largely replaced by fat, drastically reducing the production of naïve T cells. These are the cells that recognize new pathogens and coordinate the immune response. With fewer naïve T cells available, the body is slower to respond to a new flu strain introduced by vaccination (Chen et al., Vaccines, 2024).

B cell dysfunction. B cells produce antibodies — the proteins that neutralize viruses. With age, B cells become less effective at producing high-affinity antibodies. The transcription factor E47, which drives antibody class switching, declines in older B cells, reducing the proportion of IgG antibodies (the type most important for viral neutralization) generated after vaccination (Aging and Vaccines, 2026).

Chronic low-grade inflammation (inflammaging). Paradoxically, while specific immune responses weaken, the baseline level of inflammation in the body increases with age. Elevated levels of pro-inflammatory cytokines (IL-6, TNF-α, CRP) create a noisy immunological environment that interferes with the precise signaling needed for a targeted vaccine response. This state, called inflammaging, has been linked to reduced antibody titers after both influenza and pneumococcal vaccination (Solana et al., Semin Immunol, 2015).

Reduced germinal center activity. Germinal centers are the microscopic structures in lymph nodes where B cells undergo selection and maturation after encountering an antigen. In older adults, germinal center reactions are less robust, producing fewer long-lived plasma cells and memory B cells. This means even when an older adult mounts an initial antibody response to a flu vaccine, the response may not last through the entire flu season (Connors et al., Aging, 2021).

The practical result of all this: a standard 15 µg flu vaccine may produce antibody titers in older adults that are 50–75% lower than those seen in younger adults given the same vaccine. The high-dose formulation directly addresses this gap by flooding the immune system with a larger antigenic stimulus, increasing the probability that enough B cells will be activated to produce a protective level of antibodies.

High-Dose Flu Vaccine vs Regular: What the Clinical Trials Found

The clinical evidence for the high-dose flu vaccine now spans more than a decade and includes multiple randomized controlled trials involving hundreds of thousands of participants across several countries.

The 2014 NEJM Trial (DiazGranados et al.)

The foundational trial was published in the New England Journal of Medicine in 2014. This randomized, double-blind study enrolled 31,989 adults aged 65 and older across 126 sites in the United States and Canada over two flu seasons. Results showed the high-dose vaccine was 24.2% more effective at preventing laboratory-confirmed influenza compared to the standard dose (95% CI: 9.7–36.5%). Post-hoc analyses also showed reductions in hospitalizations for pneumonia and influenza-related complications (DiazGranados et al., NEJM, 2014;371:635–645).

This was the trial that led to the FDA’s approval of the high-dose formulation and ultimately to ACIP’s preferential recommendation.

The 2015 Medicare Beneficiary Study (Izurieta et al.)

Real-world effectiveness data from the Centers for Medicare and Medicaid Services (CMS) added another layer. A retrospective cohort study of 2.5 million Medicare beneficiaries found that high-dose vaccine recipients had a 22% lower risk of influenza-related hospitalization compared to standard-dose recipients during the 2012–2013 season (Izurieta et al., Clin Infect Dis, 2015;60:1530–1540). This was significant because it demonstrated effectiveness outside the controlled environment of a clinical trial, in the messy reality of everyday clinical practice.

The 2025 Denmark Trial (Johansen et al.)

The largest trial to date was published in the NEJM in 2025. This pragmatic, open-label, randomized trial conducted in Denmark across the 2022–2023, 2023–2024, and 2024–2025 flu seasons enrolled 332,438 adults aged 65 and older. The primary endpoint — hospitalization for influenza or pneumonia — occurred in 0.68% of the high-dose group versus 0.73% of the standard-dose group. The relative vaccine effectiveness was 5.9% (95.2% CI: −2.1 to 13.4; P=0.14), which did not reach statistical significance (Johansen et al., NEJM, 2025;393:2291–2302).

This result generated considerable discussion among epidemiologists. Some noted that the open-label design (participants knew which vaccine they received) introduced potential bias. Others pointed out that Denmark had relatively low influenza activity during parts of the study period, reducing the statistical power to detect a small difference. The trial did not disprove efficacy; rather, it highlighted the difficulty of detecting modest incremental benefits in a pragmatic setting.

The 2025 Spain Trial (Pardo-Seco et al.)

Published in the same issue of the NEJM, this Spanish randomized trial enrolled over 600,000 adults aged 65 and older across three flu seasons. In contrast to the Denmark trial, this study found a statistically significant reduction in influenza-related hospitalizations with the high-dose vaccine (Pardo-Seco et al., NEJM, 2025;393:2303–2312).

2026 Meta-Analysis (Lancet Healthy Longevity)

A systematic review and meta-analysis published in The Lancet Healthy Longevity in 2026 pooled data from 14 randomized controlled trials, including both the Denmark and Spain studies. The analysis found that the high-dose vaccine provided a small but consistent reduction in hospitalizations for influenza or pneumonia in adults 65+, with an estimated relative vaccine effectiveness around 6–12% depending on the outcome definition. For mortality, the pooled data did not show a statistically significant difference, though the confidence intervals were wide due to relatively low event rates (Lancet Healthy Longevity, 2026).

High-Dose Flu Vaccine Side Effects

The high-dose vaccine produces more frequent local reactions than the standard dose. This is expected — a four-fold increase in antigen concentration triggers a larger inflammatory response at the injection site.

Local Side Effects

In the 2014 NEJM trial, high-dose recipients reported higher rates of pain at the injection site (36% vs 24%), along with increased redness and swelling. These effects were typically mild and resolved within 1–3 days. They reflect the immune system responding to the larger antigen dose, not an indicator of a dangerous reaction.

Systemic Side Effects

Systemic effects — fever, muscle aches, headache, and fatigue — occurred at roughly similar rates between the high-dose and standard-dose groups. In most studies, the difference in systemic reactions was not statistically significant. The high-dose vaccine does not appear to carry a meaningfully different systemic side-effect profile compared to standard vaccines.

Serious Adverse Events

Across all clinical trials, serious adverse events were not more common with the high-dose formulation. As with all injectable vaccines, anaphylaxis is theoretically possible but extremely rare — roughly 1–2 cases per million doses administered, a rate consistent across all inactivated flu vaccines.

A Note on VAERS Reports

The Vaccine Adverse Event Reporting System (VAERS) is a passive surveillance system maintained by the CDC and FDA. Anyone — patients, family members, healthcare providers — can submit a report. VAERS data represent unverified reports and cannot establish causation. A VAERS report of an adverse event following vaccination does not mean the vaccine caused the event.

The original claim that circulated online — that “105 seniors died after receiving a high-dose flu shot” — was based on misinterpreted data from the vaccine’s pre-licensure clinical trial. In clinical trials of this size (involving tens of thousands of elderly participants), deaths are expected in both treatment and control groups simply because the participants are elderly and have underlying health conditions. The death rate in the high-dose group was not higher than in the standard-dose group. Regulatory authorities (the FDA and the EMA) reviewed this data and concluded there was no safety signal.

How the High-Dose Vaccine Compares to Other Enhanced Flu Vaccines

The high-dose vaccine is not the only option designed for older adults. Two other formulations also carry ACIP’s preferential recommendation for adults 65+:

Fluad (adjuvanted vaccine) uses MF59, an oil-in-water emulsion adjuvant, to enhance the immune response without increasing the antigen dose. Real-world data from Denmark during the 2024–2025 season showed the adjuvanted vaccine had an overall effectiveness of 48% against lab-confirmed influenza A in adults 65+, compared to 33% for standard-dose and 50% for high-dose — suggesting all three enhanced vaccines perform at roughly the same level and are all substantially better than a standard-dose shot (Eurosurveillance, 2025).

Flublok (recombinant vaccine) uses a different manufacturing process entirely. Instead of growing virus in chicken eggs (which can introduce mutations that reduce vaccine effectiveness), Flublok produces hemagglutinin protein in insect cells using recombinant DNA technology. This eliminates egg-adapted changes and produces a purer antigen. The vaccine contains 45 µg per strain — three times the standard dose — and is suitable for people with severe egg allergies.

mRNA Flu Vaccines: The Newest Option

For the 2026–2027 season, the first mRNA influenza vaccine (mFLUSIVA, by Moderna) is available for adults 50 and older after receiving FDA approval. In Phase 3 trials involving about 40,000 adults, mFLUSIVA showed 26.6% greater effectiveness than standard-dose flu vaccines in adults 50–64 and 27.4% greater effectiveness in adults 65+ (Empire Care, 2026). The AAFP includes mRNA flu vaccines among its preferred options for adults 65+, although as of mid-2026, CDC’s formal preferential recommendation still names only the three established options (high-dose, adjuvanted, recombinant).

No head-to-head trial has yet compared mFLUSIVA directly with Fluzone High-Dose.

Is There a High-Dose Flu Vaccine This Year?

Yes. For the 2026–2027 flu season, the CDC’s Advisory Committee on Immunization Practices (ACIP) continues to recommend that all adults aged 65 and older receive a high-dose, adjuvanted, or recombinant flu vaccine rather than a standard-dose shot. Fluzone High-Dose Quadrivalent remains one of three preferentially recommended options for this age group (CDC Interim Clinical Considerations, 2026–2027).

If none of these three vaccines is available at the time of the visit, ACIP says any age-appropriate flu vaccine should be used. A standard-dose flu vaccine is still far better than no vaccine.

Medicare Part B covers all FDA-approved seasonal flu vaccines for adults 65+, with no out-of-pocket costs when coverage requirements are met. This coverage is a statutory benefit and does not depend on ACIP’s preferential recommendation.

How Flu Vaccine Effectiveness Varies by Season

One source of public confusion about flu vaccines is that their effectiveness changes each year — sometimes dramatically. This is not a defect in the vaccine itself; it reflects the biology of the influenza virus.

Influenza undergoes constant genetic drift, and the vaccine strains chosen each February (for the Northern Hemisphere season) are based on WHO surveillance data predicting which strains will circulate in the coming fall and winter. In years when the prediction is accurate, vaccine effectiveness may reach 40–60%. In years when the circulating strain has drifted away from the vaccine strain — as frequently happens with H3N2 — effectiveness may drop to 10–20%.

This variability applies to all flu vaccines, including the high-dose formulation. The high-dose vaccine improves a person’s antibody response relative to a standard-dose shot, but it cannot overcome a fundamental mismatch between vaccine and circulating strains.

For context, CDC’s Flu Vaccine Effectiveness Network reported overall vaccine effectiveness estimates ranging from 10% (2018–2019, H3N2-dominated) to 52% (2022–2023, mixed) over recent seasons. These figures underline a basic reality: flu vaccination reduces risk, but does not eliminate it. Even in good match years, some vaccinated individuals will get the flu — though they are less likely to be hospitalized or die from it.

Cardiovascular Benefits of Flu Vaccination in Older Adults

An emerging area of research concerns the cardiovascular benefits of influenza vaccination, particularly for older adults with heart disease. Influenza infection triggers systemic inflammation that can destabilize arterial plaques, increasing the risk of heart attack and stroke. Several meta-analyses have found that flu vaccination reduces cardiovascular events in patients with existing heart disease.

A 2023 meta-analysis in the European Journal of Heart Failure (Modin et al.) found that influenza vaccination was associated with a significant reduction in cardiovascular death among patients with ischemic heart disease and heart failure. A 2025 European Society of Cardiology clinical consensus statement went further, characterizing influenza vaccination as “a new form of cardiovascular prevention” — placing it alongside statin therapy and blood pressure management as a tool for reducing cardiac risk (referenced in NEJM 2025 Denmark trial citations).

Whether the high-dose vaccine provides greater cardiovascular protection than standard-dose remains an active research question. The Denmark trial did examine cardiovascular endpoints but did not find a significant difference. However, several observational studies have suggested a trend toward fewer cardiovascular events with high-dose vaccination.

Who Should Not Get the High-Dose Flu Vaccine

The high-dose vaccine carries the same contraindications as standard inactivated flu vaccines:

Severe allergic reaction to a previous dose. Anyone who has had anaphylaxis or a severe allergic reaction after a prior flu vaccine (of any type) should not receive another dose without consulting an allergist.

Severe egg allergy (with caveats). The high-dose vaccine is produced using egg-based technology. However, current ACIP guidelines no longer require a waiting period or special setting for egg-allergic individuals receiving inactivated flu vaccines, regardless of the severity of the egg allergy. The amount of egg protein (ovalbumin) in injectable flu vaccines is extremely small (typically ≤1 µg/dose) and multiple studies have shown these vaccines are safe for egg-allergic individuals. For those who prefer an egg-free option, Flublok (recombinant) is available.

Age under 65. The high-dose vaccine is licensed for adults aged 65 and older only. Younger adults should receive a standard-dose vaccine. (The ACIP does allow high-dose or adjuvanted vaccines for solid organ transplant recipients aged 18–64 who are on immunosuppressive medications, though this is off the primary recommendation pathway.)

Current moderate-to-severe acute illness. As with all vaccines, vaccination should be deferred during an acute illness with fever, though mild illness (e.g., a cold without fever) is not a reason to postpone.

Common Questions About the High-Dose Flu Vaccine

Is the high-dose flu shot a live vaccine?

No. The high-dose flu vaccine is an inactivated (killed) vaccine. It cannot cause influenza infection. The only flu vaccine that uses weakened live virus is FluMist (nasal spray), which is not recommended for adults 65+.

Can I get the high-dose vaccine and the COVID-19 vaccine at the same time?

Yes. CDC says flu vaccines can be given at the same visit as COVID-19 vaccines. Each vaccine should be administered in a different arm (or at least at a different injection site in the same arm) to make it easier to identify the source of any local side effects.

Does the high-dose vaccine contain thimerosal?

For the 2026–2027 season, CDC recommends only single-dose formulations, which are thimerosal-free. Multi-dose vials, which may contain thimerosal as a preservative, are being phased out. The amount of thimerosal in multi-dose flu vaccines (ethylmercury, not methylmercury) has never been linked to any adverse health effects in scientific studies, but single-dose formulations are now standard practice.

Does the high-dose vaccine work against bird flu (H5N1)?

No. Seasonal flu vaccines, including the high-dose version, target circulating human influenza strains (H1N1, H3N2, and influenza B). They do not provide protection against avian influenza H5N1, which has a different hemagglutinin subtype. Separate candidate vaccines for H5N1 are under development and have been stockpiled by governments for pandemic preparedness.

Can I still get the flu after a high-dose vaccine?

Yes. No flu vaccine is 100% effective. The high-dose vaccine reduces the risk of getting the flu and substantially reduces the risk of serious outcomes (hospitalization, pneumonia, death) if you do get infected. Think of it as wearing a seatbelt: it does not prevent all injuries, but it dramatically reduces the chance of the worst outcomes.

The Bottom Line

The high-dose influenza vaccine represents one of the clearest applications of a simple principle in immunology: when the immune system is weaker, give it more to work with. For adults 65 and older — the age group that suffers the vast majority of flu-related deaths and hospitalizations — the extra antigen dose translates to measurably better protection compared to standard-dose vaccines, even if the absolute benefit is modest in any given year.

The CDC, ACIP, AAFP, and multiple international health agencies agree: older adults should receive an enhanced flu vaccine (high-dose, adjuvanted, or recombinant) rather than a standard-dose shot. But the most important decision is not which flu vaccine to get — it is whether to get vaccinated at all. In the United States, flu vaccination coverage among adults 65+ was approximately 75% in recent seasons, meaning one in four older adults enters each flu season unprotected. For those individuals, any flu vaccine would be a significant improvement.

References

1. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. N Engl J Med. 2014;371:635–645. doi:10.1056/NEJMoa1315727
2. Izurieta HS, Thadani N, Shay DK, et al. Comparative Effectiveness of High-Dose vs Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries. Clin Infect Dis. 2015;60(10):1530–1540. doi:10.1093/cid/civ098
3. Johansen ND, Modin D, Loiacono MM, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. N Engl J Med. 2025;393:2291–2302. doi:10.1056/NEJMoa2509907
4. Pardo-Seco J, Rodríguez-Tenreiro-Sánchez C, Giné-Vázquez I, et al. High-Dose Influenza Vaccine to Reduce Hospitalizations. N Engl J Med. 2025;393:2303–2312. doi:10.1056/NEJMoa2502680
5. Effect of High-Dose versus Standard-Dose Influenza Vaccines on Hospitalisation Outcomes and Mortality in Older Adults: A Systematic Review and Meta-Analysis. Lancet Healthy Longevity. 2026. doi:10.1016/S2666-7568(26)00054-1
6. Chen L, Shao C, Li J, Zhu F. Impact of Immunosenescence on Vaccine Immune Responses and Countermeasures. Vaccines. 2024;12(11):1289. doi:10.3390/vaccines12111289
7. Falahi S, Abdoli A, Kenarkoohi A. Immune Aging, Immunosenescence, and Inflammaging: Implications for Vaccine Response in Older Adults. Health Sci Reports. 2025;8(7):e71119. doi:10.1002/hsr2.71119
8. Connors J, Haddad EK, Petrovas C. Aging Alters Immune Responses to Vaccines. Aging. 2021;13(3):4107–4125. doi:10.18632/aging.202598
9. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate Immunosenescence: Effect of Aging on Cells and Receptors of the Innate Immune System in Humans. Semin Immunol. 2012;24(5):331–341. PubMed
10. CDC. Interim Clinical Considerations for the Use of Seasonal Influenza Vaccines — United States, 2026–2027 Season. cdc.gov
11. CDC. Flu Vaccine and People 65 Years and Older. cdc.gov
12. ACIP. Evidence to Recommendations Framework: Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged ≥65 Years. cdc.gov
13. Enhanced Influenza Vaccines Impact Effectiveness in Individuals Aged 65 Years and Older, Denmark, 2024/25 Influenza Season. Eurosurveillance. 2025. PMC
14. Modin D, Lassen MCH, Claggett B, et al. Influenza Vaccination and Cardiovascular Events in Patients with Ischaemic Heart Disease and Heart Failure: A Meta-Analysis. Eur J Heart Fail. 2023;25:1685–1692.
15. Protection against Influenza Hospitalizations from Enhanced Influenza Vaccines among Older Adults: A Systematic Review and Network Meta-Analysis. J Am Geriatr Soc. 2024. PMC

Understanding Flu Vaccine Manufacturing and Strain Selection

Most flu vaccines — including the high-dose version — are still manufactured using chicken eggs, a method developed in the 1940s and refined over eight decades. The process works like this: WHO identifies candidate vaccine viruses based on global surveillance data, typically in February for the Northern Hemisphere season. Vaccine manufacturers receive these candidate viruses and inoculate them into fertilized chicken eggs, where the virus replicates for several days. The fluid containing the virus is then harvested, the virus is inactivated (killed), and the hemagglutinin antigen is purified and formulated into the final vaccine.

This egg-based process has one well-known limitation: influenza viruses sometimes mutate as they adapt to growing in eggs. The H3N2 subtype is particularly prone to these “egg-adapted” mutations, which can change the hemagglutinin protein enough to reduce the vaccine’s effectiveness against the circulating wild-type virus. This is one reason H3N2-dominated seasons tend to produce lower overall vaccine effectiveness numbers. The recombinant vaccine (Flublok) avoids this problem entirely by producing hemagglutinin protein in insect cell culture rather than eggs, ensuring the vaccine antigen precisely matches the target virus.

For the high-dose vaccine, the egg-based manufacturing process is the same, but four times as much purified hemagglutinin is included in each dose. This means more eggs are needed per dose — a logistical consideration that historically limited supply. Manufacturing capacity has expanded significantly since the vaccine’s 2009 approval, and supply shortages are uncommon for recent flu seasons, though availability may vary by region and time of season.

Why Flu Vaccines Must Change Every Year

Unlike measles or hepatitis B vaccines, which provide long-lasting immunity against a stable virus, flu vaccines must be reformulated annually. This is because influenza viruses mutate constantly through a process called antigenic drift. Small changes in the hemagglutinin and neuraminidase surface proteins allow the virus to evade immune recognition from previous infections or vaccinations. Occasionally, more dramatic changes (antigenic shift) produce entirely new subtypes, as occurred with the 2009 H1N1 pandemic.

The WHO Global Influenza Surveillance and Response System (GISRS) operates year-round, collecting and analyzing influenza samples from 143 National Influenza Centers in 113 countries. Twice a year — in February for the Northern Hemisphere and in September for the Southern Hemisphere — WHO convenes an expert panel to recommend which virus strains the vaccines should target. This recommendation is based on which strains are circulating most widely, which are spreading to new regions, and which show antigenic changes that might make previous vaccines less effective.

This surveillance-and-prediction cycle is one of the most impressive feats of global public health coordination, but it is not infallible. The February strain selection must predict which viruses will circulate eight to nine months later. When the prediction matches well, vaccine effectiveness is higher. When the virus drifts between February and the following winter, effectiveness drops. The high-dose vaccine cannot overcome a poor strain match, but it gives older adults a better shot at generating protective antibody levels against whatever strains the vaccine targets.

Flu Vaccination Rates in Older Adults: Where Things Stand

Despite clear evidence of benefit and universal recommendations from health authorities, flu vaccination coverage among older adults in the United States has stagnated. According to CDC data, approximately 75% of adults 65 and older received a flu vaccine during recent seasons — the highest coverage of any adult age group, but still leaving roughly 15 million older Americans unvaccinated each year.

Coverage varies substantially by race and ethnicity. White adults 65+ have the highest vaccination rates (around 76%), while Black adults in the same age group have rates around 60%, and Hispanic adults around 62%. These disparities are well-documented and reflect a combination of factors: access to healthcare, trust in medical institutions, insurance coverage (though Medicare covers flu vaccines without copay), transportation barriers, and historical experiences that affect willingness to seek preventive care.

Among those older adults who do get vaccinated, uptake of enhanced vaccines (high-dose, adjuvanted, or recombinant) has increased since ACIP’s 2022 preferential recommendation. However, many pharmacies and clinics still stock standard-dose vaccines alongside enhanced options, and patients are not always informed about the recommendation for enhanced vaccines. If you are 65 or older and a provider offers you a standard-dose flu vaccine, it is worth asking whether a high-dose, adjuvanted, or recombinant option is available.

Timing: When Should Older Adults Get the Flu Shot?

CDC recommends flu vaccination in September or October for most people. Getting vaccinated too early (July or August) raises the possibility that immunity may wane before the end of flu season, particularly in older adults whose immune responses are already less durable. However, vaccination should continue to be offered throughout the flu season — even into January or February — because the timing of peak flu activity varies from year to year.

For older adults specifically, the balance between “early enough to be protected when flu arrives” and “not so early that immunity fades” is important. Antibody levels typically peak about two weeks after vaccination and begin to decline over the following months. A September or early October vaccination generally provides adequate protection through the typical peak months of December through February, with some residual protection into March.

People who were not vaccinated by October should not assume the window has closed. Late vaccination is far better than no vaccination, particularly in seasons when flu activity peaks later than expected.

What Happens If You Skip the Flu Vaccine?

For older adults, the consequences of forgoing flu vaccination can be severe. The 2017–2018 flu season was among the worst in recent memory: an estimated 61,000 Americans died from influenza, with the vast majority of deaths occurring among adults 65 and older. Hospitalizations topped 810,000 nationally. During that season, overall vaccine effectiveness was only 38% — but the estimated number of flu-related hospitalizations prevented by vaccination was still approximately 91,000.

Even a modestly effective vaccine, widely deployed, prevents tens of thousands of hospitalizations and thousands of deaths each year. For an individual older adult, the calculation is straightforward: the flu shot carries a low risk (a sore arm for a day or two) and a meaningful benefit (reduced chance of a hospital stay or worse). The high-dose version makes that benefit somewhat larger, at the cost of a slightly higher chance of the sore arm.

Looking Ahead: The Future of Flu Vaccination for Older Adults

Research into improved flu vaccines continues on several fronts. The approval of the first mRNA flu vaccine (mFLUSIVA) in 2026 marked the beginning of a new generation of influenza vaccines that can be manufactured faster and potentially updated more easily than egg-based products. Because mRNA vaccines encode the genetic instructions for the target protein rather than requiring months of virus cultivation, they could theoretically be produced in weeks rather than months — a meaningful advantage when a new variant emerges or when the initial strain selection proves to be a poor match.

Longer-term, researchers are pursuing a “universal” flu vaccine that would target a conserved part of the influenza virus — such as the stalk region of the hemagglutinin protein, which changes much less between seasons than the head region that current vaccines target. A universal vaccine could potentially provide multi-year protection and eliminate the need for annual reformulation. Several candidates are in clinical trials, though none has reached Phase 3 yet. If successful, a universal flu vaccine would be particularly beneficial for older adults, who bear the greatest burden from annual flu outbreaks and whose immune systems may not rebuild strong protection each year from seasonal revaccination.

Until that day arrives, the available data point clearly in one direction for adults 65 and older: get a flu vaccine every year, and when possible, get an enhanced formulation — high-dose, adjuvanted, or recombinant — rather than a standard-dose shot.

Last updated: September 26, 2026